ALDH1A1 and non-small cell lung carcinoma: To further assess the functional effects of ALDH1 inhibition in cisplatin resistant NSCLC, cisplatin resistant sublines were treated with increasing concentrations of cisplatin (0-100μM) alone, and in combination with DEAB (15μM).